VIP方案治疗晚期非小细胞肺癌  

VIP Regimen in the Treatment of Advanced Non-Small Cell Lung Cancer

作　　者：赵文英[1] 王潞[1] 吉兆宁 

机构地区：[1]附属弋矶山医院肿瘤内科,241001

出　　处：《皖南医学院学报》2000年第2期100-101,共2页Journal of Wannan Medical College

摘　　要：采用VIP联合化疗方案治疗晚期复治的非小细胞肺癌24例。结果：CR1例，PR9例，NC9例，PD5例。有效率41．67％（10／24）。毒性反应主要是骨髓抑制及消化道反应。加用Mesna后，全组未出现肉眼血尿。提示VIP方案治疗晚期复治的非小细胞肺癌有较好疗效，值得推广使用。Twenty-four patients with advanced and recurrent non-small cell lung cancer (NSCLC)were treated with combined-chemotherapy of etoposide (100mg, d1-5 ), Ifosfamide(2g, d1-5 ) and cisplatin (30mg, d1-5 ) (VIP regimen). A mong them one patient showed complete response, 9 showed partial response and no change response, and 5 showed progtessive disease, with an overall response rate of 41. 67% (10/24). The major toxic effects were myelosuppres sion and gastrointestinal tract reaction. No macroscopic hematuria was observed because of Mesna administered. This result suggests that VIP is an effective regimen for patients with advanced non-small cell lung cancer.

关 键 词：非小细胞肺癌 VIP方案 药物疗法 

分 类 号：R734.205[医药卫生—肿瘤] R730.53[医药卫生—临床医学]